Overview

Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients

Status:
Completed

Trial end date:
2009-03-01

Target enrollment:

Participant gender:

Summary

Demonstrate an improvement in the composite scores of validated neurocognitive tests in elderly subjects with chronic sub-clinical (i.e., asymptomatic) hyponatremia.

Phase:

Phase 3

Details

Lead Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Collaborator:

Otsuka Pharmaceutical Co., Ltd.

Treatments:

Tolvaptan